New Joint Health Chewable Supplement From Valensa

Tuesday, August 9, 2016 Research News
Email Print This Page Comment bookmark
Font : A-A+

An Easy-to-Ingest "Full Spectrum" Alternative to Glucosamine/ Chondroitin Tablets

ORLANDO, Fla., Aug. 9, 2016 /PRNewswire/ -- Valensa International today announced the addition of Flex Pro ES™ Chewables

to its Flex Pro family of joint health products. Flex Pro ES™ Chewables provide multiple modes of support for joint health, leveraging the benefits of Zanthin® Natural Astaxanthin, Flexuron™, a proprietary super effective immune-stimulating type of Hyaluronate as well as a Hydrolyzed eggshell membrane that delivers collagen, elastin and elastin precursors. The pleasant-tasting, sugar-free tablet is a full-spectrum, chewable solution to better joint health featuring therapeutic amounts of each key component. It is formulated to contain the building blocks for joint tissue repair, to support synovial fluid health, and to provide antioxidants that address oxidative stress and Chronic Low Level Inflammation issues (CLLI). The recommended usage for joint comfort is one chewable per day, however, up to 4 chewable tablets per day may be consumed. Flex Pro ES™ Chewables are available as bulk tablets, in blister packs and turnkey bottled SKUs for brands and marketers who want to offer them in a variety of channels, including Mass Market, Practitioner, Ecommerce and Direct.

Photo -

According to Dr. Rudi E. Moerck, President and CEO of Valensa, the chewable form of Flex Pro ES™ allows a broader and growing group of people to take advantage of one of the most successful joint health formulas introduced to the market in the last five years.  "About 40 percent of Americans have issues swallowing pills, while some people have diets where fluid intake is limited. For some people, swallowing issues are severe enough to prevent them from using pills altogether. Industry standard glucosamine chondroitin-based products have not been successfully delivered as chewables to date and many other leading joint health ingredients have taste issues," he said. "Flex Pro ES™ Chewables offer a unique delivery system in the form of a great tasting, sugar-free chewable tablet. The product is a perfect solution for those who have difficulty swallowing. They are ideal for diabetics, seniors and people on-the-go," he added. Dr. Moerck went on to say that, in addition to targeting older consumers with joint health issues, Flex Pro ES™ Chewables have additional applications in the Sports Nutrition market.

Valensa Now Sourcing Pure California Astaxanthin Raw Material

Valensa, a leading manufacturer of Natural Astaxanthin extract, offers very high quality extraction with a unique, proprietary, two-part process using all-natural Deep Extract® (high pressure) supercritical CO2 (ethanol and solvent free). Valensa's O2B® Peroxidation Blocker stabilization technology ensures long-term stability of 4 years and efficacy for the consumer. Most of Valensa's Astaxanthin raw material has been sourced from the company's facility located in coastal Chile. In response to market demand, the company has added a new source of raw materials from a California facility that develops the material exclusively for Valensa under its strict quality control standards. All of Valensa's Astaxanthin is extracted at the company's Florida facility.

According to Moerck, all Astaxanthin products are not the same when it comes to purity and stability. "Buyers of Astaxanthin should be concerned about some new sources of the ingredient that are coming onto the market. When Valensa formulates with this powerful antioxidant, we only use algae from several verified clean sources, including our own, and an extraction that meets rigorous international standards. There are several, good clean sources of the ingredient on the market today – from companies using a supercritical CO2 extraction process. Claims of purity should be examined closely – with independent analyses if necessary. Consumer trust in our industry is too important to leave to empty promises or a lower price," he said.

For further information, contact:Dr. Rudi Moerck, President & CEOVoice: 210-632-0695Fax:

To view the original version on PR Newswire, visit:

SOURCE Valensa International

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store